Rheumatoid arthritis (RA)
Introduction
RA is a debilitating chronic inflammatory synovial joint disease that affects about 1% of the world's population [1] . The disease usually affects the small joints of the hands and feet. The etiology of the disease is unknown. The chronic inflammation causes invasion of synovial membrane toward articular bone which results in the formation of a layer of granulation tissue, called pannus. Further, the inflammation would induce irreversible damage of the a1111111111 a1111111111 a1111111111 a1111111111 a1111111111
Methods

Creation of a human PPI database
We created a human PPI database by extracting the interactions from six publicly available databases, namely HPRD, BioGRID, IntAct, MINT, STRING and CRG [36] [37] [38] [39] [40] [41] . From each database, only the experimentally determined physical interactions in human cells were considered. The experimental methods used for determining the protein interactions that are listed in each database are given in the S1 File. All these interactions were merged into a single database by converting the protein identifiers of individual databases into gene symbols. In HPRD and BioGRID the proteins are represented with their respective gene symbols. In other databases the different protein identifiers were converted into gene symbols before merging. For instance, in IntAct and MINT databases, the proteins are identified with their respective UniProtKB entries. They were converted into gene symbols by using a HUGO gene nomenclature committee (HGNC) custom downloaded file containing gene symbols and UniProtKB entries [46] . Similarly, in the STRING and CRG databases the proteins are represented with the Ensembl protein and Ensembl gene identifiers respectively, and were converted into gene symbols with the aid of the Ensembl Biomart project [47] . All these interactions have been merged based on their gene symbols to create a final human PPI database. The database is in the S2 File.
Creation of a synovial tissue-specific PPI database for the plasma membrane and cytoplasm
In this study, we have focused on creating a cytokine signaling network starting from the binding of the cytokines to their cell surface receptors and ending with the activation of the transcription factors in the cytoplasm. Therefore we aim to create a PPI interactome that is specific to the plasma membrane and the cytoplasm. For this, only the interactions of those proteins that get localized to the cytoplasm and the plasma membrane were extracted from the human PPI database using the subcellular localization data present in the mammalian protein subcellular localization database, LOCATE [48] . We also extracted the interactions of many cytokine receptors and transcription factors that are not listed in LOCATE. A list of the genes of this interactome, called the 'G-list', was prepared. Furthermore, to make this interactome specific to the synovial tissue, we computed the co-expression of the interacting partners of these interactions by analyzing the RA related microarray gene expression data obtained from GEO. All the microarray datasets chosen in this study are based on the Affymetrix platform. Further details about the microarray datasets and their analysis are provided at the end of the 'Methods' section. For every microarray dataset, we did the following; for a pair of genes in the G-list we computed the Pearson correlation coefficient of the gene expression values across all RA disease samples. The correlations were computed for all possible pairs in the G-list. This was repeated for all the datasets. Only those pairs that had experimentally determined PPI interactions and with a Pearson correlation coefficient > 0.7 in at least one microarray dataset were considered as co-expressed in the synovial tissues. Finally, a synovial tissue-specific PPI database was created by selecting the interactions of the co-expressed interacting proteins.
Based on a literature search in PubMed, we identified 12 active cytokines and 8 of their transcription factors in RASF. Details of these cytokines and their transcription factors are described in the Results section and the list of search terms used is in S3 File.
Considering these cytokines and their transcription factors as sources and targets respectively, we extracted all the shortest paths from the sources to the targets from the SPPIN network using the Breadth-first search (BFS) algorithm. In addition to BFS, there are several other approaches for finding shortest paths in graphs. Some of them are Depth-first search (DFS), Dijkstra and A Ã [49] . DFS puts the visited vertices in a stack while BFS puts them in a queue. The BFS algorithm is generally used for finding shortest paths in unweighted PPI networks. In SPPIN, the sources and the targets are closer to one another, which is an ideal scenario for using the BFS algorithm. This algorithm is computationally faster for searching shortest paths in SPPIN.
Each shortest path extracted from SPPIN contains the receptor of the source cytokine, the target transcription factor and the intermediate proteins that connect them. If a cytokine receptor is encoded by more than one gene, all the shortest paths between each of the cytokine receptor genes and their respective transcription factors were considered. Similarly, if a transcription factor is encoded by more than one gene, all the shortest paths between the cytokine receptor and each of these genes were considered. There were a total of 103 distinct intermediate proteins in the shortest paths. Each of these intermediates was treated as a focal node and all of the latter's immediate neighborhood nodes were isolated. Finally, we formed the cytokine network by connecting the cytokines, their transcription factors, the intermediates that connect them and the neighborhood nodes of the intermediates [Fig 1] . We named this network the 'cytokine PPI network' (CPPIN).
Centrality measures
In order to identify the highly connected and central proteins in the network, we measured four important centralities of every node present in the network as described below.
Degree centrality. Degree centrality is the number of edges through which a node connects to other nodes within a network. Proteins with a high degree are connected to a large number of other proteins. In PPI networks, proteins with a higher degree are considered 'essential proteins' or 'hubs' as they are located at the center of the network [50] . Considering the pair-wise interactions of 'n' nodes, the degree centrality of a node p k is calculated using the following equation [51] .
Where a(pi, pk) = 1 if and only if protein pi and protein pk are connected by an edge. Otherwise it is 0. 'n' is the total number of nodes present in the network.
Betweenness centrality. Betweenness centrality is the measure of the number of shortest paths that pass through a node within a network. Nodes with high betweenness, called 'bottlenecks', control the flow of information within a network [52] . The betweenness of a node 'n' takes the node pairs such as (n1, n2) and calculates all the shortest paths that go through 'n' to connect n1 and n2. The betweenness of a node 'n' is calculated using the following equation. Where, 'g n1, n, n2 ' is the number of shortest paths that pass through node 'n' and 'g n1, n2 ' is the total number of shortest paths. Building cytokine PPI network (CPPIN) in RA synovial fibroblasts (RASF). CPPIN was built using the publicly available PPI data. For building this network, 12 cytokines and eight of their target transcription factors that are active in RASF Closeness centrality. Closeness centrality is a measure of the average distance of all the shortest paths between a node and every other node within a network. It gives how far a certain node is from all other nodes [51] . This is calculated using the following equation.
Where, g n i represents the shortest paths between the node 'n' and every other node i. Closeness centralities are measured for all the nodes present within the CPPIN network.
Eigenvector centrality. Eigenvector centrality measures the influence of a node within a network. The node with a high eigenvector is considered the central and influential node as it is connected to many other central nodes [53] . Eigenvector centrality scores are the elements of the first eigenvector of the adjacency matrix of a network.
Microarray data analysis
In this study, we have considered five Affymetrix RA related microarray datasets that are available in the NCBI GEO database. They are GSE7307, GSE55457, GSE55235, GSE12021 (HGU133A) and GSE12021 (HGU133B) ( Table 1) . These microarray experiments were carried out on RA and normal synovial fibroblasts by other workers. The RA samples used in these studies were obtained by tissue excision upon joint replacement/synovectomy surgery from RA patients whereas the control samples were obtained from either postmortem joints or traumatic joint injury cases. We re-analyzed these datasets using the R/Bioconductor statistical package. All the datasets were normalized using two algorithms, MAS5 and RMA, separately. The differential expression of the genes between RA and control groups was computed using the two sample independent t-test.
For the co-expression analysis described above, we considered the RMA normalized expression values from the disease samples of each microarray dataset.
A gene is said to be differentially expressed in a dataset if it satisfies the following criteria: (i) Gene should have a P-value < 0.05 and a fold-change > 1.5 for up or down regulation. (ii) A gene is said to be up-regulated if it shows up-regulation by both the normalization methods were considered. In the figure, the upper half shows the steps involved in the creation of CPPIN while the lower half is a representation of CPPIN. First, the network SPPIN was created by applying two filters to the collated interactions from the six PPI databases. The two filters are (i) plasma membrane and cytoplasm subcellular localization and (ii) synovial tissue coexpression using microarray data. For creating CPPIN from SPPIN, the shortest paths between cytokines and target transcription factors and the neighboring nodes of the shortest path intermediates were used. In the lower half of the figure, the rectangles represent cytokines, the Y-shaped symbols represent the cytokine receptors, the red colored vertical ovals represent the intermediate proteins that connect the cytokine receptors and the transcription factors, the green circles represent the neighborhood nodes of the intermediate proteins and the pentagons represent the target transcription factors of the cytokines. 
Results
Construction of the CPPIN network
As explained in the 'Methods', we combined interactions from all the six resources to obtain a complete dataset. By doing this, we obtained 77218 interactions from CRG, 39042 from HPRD, 298802 from BioGRID, 89355 from STRING and 45896 from both the IntAct and MINT databases. Overall, we considered 363,476 non-redundant interactions from the six resources (S2 File). Interactions from all these six resources seem to be comprehensive. Then, two filters were applied to this data: (i) plasma membrane and cytoplasm subcellular localization and (ii) synovial tissue co-expression. This resulted in a synovial tissue-specific interactome with 7939 interactions. Using this, we built the synovial tissue-specific PPI network, SPPIN. In this network, the proteins and their interactions are represented as nodes and edges respectively.
Based on a literature survey, we have identified 12 cytokines and eight of their target transcription factors that are active in RASF (Table 2 ). These cytokines stimulate the RASF and activate their respective transcription factors. We considered these cytokines as the sources and their transcription factors as the targets in SPPIN. We then extracted a total of 139 shortest paths that pass through the cytokine receptors between these sources and targets. The number of intermediates on all the shortest paths was 103. The number of times each of these intermediate proteins occurred was also determined (S4 File).
We have also extracted the neighborhood nodes of the intermediates from the SPPIN network. The intermediates are considered seed nodes. All the nodes to which a seed node has a direct connection (path length 1) are extracted. Finally, we formed CPPIN by connecting the cytokines, their transcription factors, the 103 intermediates and the neighborhood nodes of the intermediates. This gave a network comprising 1204 nodes and 2155 edges. The edge list of this network is provided in S5 File.
Central nodes of the CPPIN network and their activity in the RA synovium
We have measured the four centralities of all the nodes present in the network and plotted their histograms (Fig 2) . With the histograms as reference, we have extracted approximately 20% of the nodes with the highest centralities in each category. The degree distributions of scale free networks, such as many real networks and human PPI, have a power-law tail. As a consequence of this, a few highly connected nodes exist in the whole network. Researchers generally refer to the 20% of nodes with the highest degree in a network as the hubs [50] . The degree and eigenvector histograms have a power-law tail (Fig 2) . We extended top 20% nodes to the betweenness and closeness centrality categories in order to increase the number of central nodes. This resulted in~30% (354) of the total nodes in CPPIN as the central nodes. Then we proceeded to determine how many of these nodes are differentially expressed in the RA synovium. The nodes that are selected in (a) at least three of the four centrality measures and differentially expressed in three of the five microarray datasets or (b) that are selected in at least two centrality measures and differentially expressed in at least four microarray datasets were considered the key molecules. This resulted in a total of 24 molecules (Table 3) . A concise interaction map that shows how these molecules are related to 12 cytokines and eight IFNAR1, interferon-alpha receptor alpha chain; IFNAR2, interferon-alpha receptor beta chain; IFNGR1, interferon gamma receptor 1; IFNGR2, interferon gamma receptor 2; TGFBR1, TGF beta receptor 1; TGFBR2, TGF beta receptor 2; IL2RG, interleukin-2 receptor subunit gamma; IL6R, inteleukin-6 receptor; NF-κB, nuclear factor kappa-light-chain-enhancer of activated B cells; STAT1, signal transducer and activator of transcription 1; AP-1, activator protein 1; IRF3, interferon regulatory factor 3; STAT3, signal transducer and activator of transcription 3; IRF7, interferon regulatory factor 7; IRF1, interferon regulatory factor 1 https://doi.org/10.1371/journal.pone.0199530.t002
transcription factors, and among them, is shown in Fig 3 . This map can also be visualized in cytoscape using the S6 File.
Directionality of differential expression for cytokine-transcription factor shortest path molecules
Since all the 12 cytokines are known to induce signal transduction pathways in RASF, all the shortest paths-between a given cytokine and transcription factor pair-seem to be important. However, some of these paths have the molecules with the same directionality (up-or downregulated) of differential expression between RA and normal samples in synovial microarray datasets (Figs 4-6). Some cytokine and transcription factor pair shortest paths have higher number of up-regulated molecules over down-regulated molecules (Figs 7 and 8 ). Some other paths have higher number of down-regulated molecules over up-regulated molecules . From this we can conclude that all these pathways are getting affected in RA. Some are active because they have a high proportion of up-regulated molecules; some others are inactive because they have a high proportion of down-regulated molecules; few of them are dysregulated because they have both up-and down-regulated molecules. 
Effects of medical therapy initiation on gene expression
Except for GSE7307 and GSE55235, each RA patient belonging to other microarray studies considered in this study has undergone different combinations of medical therapies. The details of therapies are in Table 4 . The therapies initiated on the patients are non-steroidal anti-rheumatic drug (NSARD), Azulfidine (AZ), Prednisolone (PS), Methotrexate (MTX), Cox-2 inhibitor (CX), Quensyl (QS), non-steroidal anti-inflammatory drug (NSAID) and Tilidin (T). Some patients within a dataset were treated with the same combination of therapies while others were treated with different combinations. To find out how these therapies could have affected the gene expression of 24 key molecules, the samples in each dataset were hierarchically clustered based on the expression values. In GSE7307, GSE55235 and except for one RA sample in GSE12021 (HGU133B), all RA and control samples were clustered into separate groups (Figs 11-13 ). In GSE12021 (HGU133A) and GSE55457, some RA samples were clustered into a separate group while others were clustered with controls ( Figs 14 and 15) , showing that there is a drug effect. In order to find the effect of medical therapies on the differential expression of genes, we removed the RA samples that were clustered with healthy controls from GSE12021 (HGU133A), GSE12021 (HGU133B) and GSE55457 datasets and repeated the differential expression analysis for the 354 genes which encode central proteins of CPPIN. With the same selection criteria of differential expression and centrality measures, all the 24 genes of key molecules were retained, and in addition, 10 other genes that encode central proteins were also selected (S1 Table) . S1-S3 Figs show the heat maps of the expression levels of these 24 genes in these three data sets after eliminating the RA samples that clustered with healthy controls. We notice the complete separation of controls from RA samples in the clusters. We conclude that the 24 genes that were differentially expressed in both the cases were not affected by the therapy initiation while the 10 other genes that were selected in the second case might have been affected.
Direct PPI links of the CPPIN key molecules with current RA drug targets
In order to determine if there are any recognized RA drug targets in the CPPIN key molecules, we have downloaded a dataset from the Therapeutic Target Database (TTD) which contains information on drug target genes that are at various stages of the drug discovery process [80] . The dataset consists of successful drug targets as well as the ones that have been studied in research projects and clinical trials for several diseases. We extracted all the drug targets of RA from this dataset and combined them with the successful RA drug targets listed in Okada et al. [81] . The resulting ensemble of 48 RA drug targets is listed in Table 5 . Two of the key CPPIN molecules, spleen tyrosine kinase (SYK) and c-Jun (JUN) are already established drug targets for RA. Among the remaining key CPPIN molecules, 12 have direct PPI links to some of the current RA drug targets (Table 6 ). So these 24 molecules can be considered potential drug targets for RA. The overall strategy that was used to come up with the key molecules is explained in Fig 16. 
Significance of overlap of key molecules with current RA drug targets
A random sample of 24 proteins was drawn from the CPPIN network and estimated their overlap with the current RA drug targets. After removing the overlaps from the 24, for the remaining proteins we determined the direct PPI links to the drug targets. We got the following results based on one million random samples:
1. The probability of getting 2 or more drug targets out of 24 randomly selected proteins is 0.0478, giving a statistical significance of less than 5%.
2. After removing overlaps, we counted the number of proteins among the remaining ones that are directly connected to drug targets in CPPIN. The probability of getting 12 or more proteins with direct connections to drug targets is found to be 2.6×10
Thus, the selection of 24 proteins by our analysis with two drug targets and at least 12 direct PPI links to drug targets has statistical significance. 
Discussion
In this study, we have built a cytokine signaling network (CPPIN) in RASF using publicly available PPI data. The CPPIN network contains 12 cytokine pathways that are active in RASF. The cytokine receptors, their transcription factors, intermediate signal transducers that connect them and the direct interacting proteins of the intermediates are part of this network. The cytokines include TNF, interleukins-IL-1α/β, IL-6, IL-17, IL-18, IL-21, IL-27 and IL-33, tumor necrosis factor superfamily member 14 (TNFSF14), three interferons (IFNα/β and IFNγ) and transforming growth factor-beta1 (TGF-β1). The transcription factors include nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), signal transducer and activator of transcription 1 (STAT1), STAT3, activator protein 1 (AP-1), interferon regulatory factor 1 (IRF1), IRF3, IRF7 and SMAD. Even though the number of cytokines considered in this study is low, they are reliable in the sense that they stimulate RASF and induce signal transduction pathways leading to the activation of their respective transcription factors. For building this comprehensive network, we have considered the PPI interactions only if the interacting participants of each interaction are co-expressed in the synovial tissues. To find the central proteins of the CPPIN network, four centrality measures, degree, closeness, betweenness and eigenvector have been measured for all the proteins of the CPPIN network. In each centrality category, approximately 20% of the proteins with high centrality scores were pulled out and the lists were merged for further analysis.
To identify the differential expression of the genes that encode the proteins with high centrality values we analyzed five microarray datasets related to RASF in the GEO database. We have used the following methodology to come up with the key molecules. A protein is considered a key molecule only if it is selected in at least three centrality measures and three microarray datasets or two centrality measures and four microarray datasets. This gave 24 key molecules. Two of these 24, namely JUN and SYK, are already drug targets for RA. Among the remaining, 12 have direct PPI links to current RA drug targets.
One of the key molecules in the list is epidermal growth factor receptor (EGFR). EGFR is down-regulated in at least five RA microarray datasets. It is also highly connected in the CPPIN network as it has high degree, betweenness and closeness centrality measures. Swanson et al. observed that inhibition of EGFR by erlotinib reduced pannus formation, synovitis, vascularisation, and cartilage and bone erosion in type-II collagen-induced arthritis (CIA) mouse models [82] [83] . Further, an earlier topological analysis of a PPI network in RA has reported that EGFR is highly relevant to RA (Tieri et al.) [84] . Another key molecule, tyrosine-protein phosphatase non-receptor type 6 (PTPN6) is up-regulated in three microarray datasets and is selected in all the four centrality measures. It also interacts with some of the current RA drug targets, janus kinase 1 and 2 (JAK1 and JAK2) and SYK. Additionally, it is found to be enriched in the synovial fluid of RA patients [85] .
Lymphocyte-specific protein tyrosine kinase (LCK) is up-regulated in four microarray datasets. It is also selected in all the four centrality measures. Further, Swanson et al. have affirmed that tyrosine kinases such as LCK are the predominant players in the cell signaling pathways that enhance inflammation and the formation of pannus in RA. They emphasized that LCK can be considered a drug target for RA [86] . Another key molecule known as colony stimulating factor 2 receptor beta (CSF2RB) is up-regulated in four microarray datasets and is selected [87] . Interleukin receptor subunit gamma (IL2RG), which interacts with at least six cytokine receptors including IL2RA, IL4RA, IL7RA, IL9RA, and IL15RA, is up-regulated in four microarray datasets and is selected in all the four centralities. In addition, Chang et al. have observed the up-regulation of IL2RG in their microarray studies on RA synovial tissues [88] . c-myc (MYC) is down-regulated in three microarray datasets and is selected in all the four centralities. It also interacts with two current RA drug targets, the conserved helix-loop-helix ubiquitous kinase (CHUK) and JUN. Hashiramoto et al. have found the involvement of c-myc in RA pathogenesis [89] . They have observed that c-myc antisense oligodeoxynucleotides (AS ODN) arrested [91] . CCR5 is up-regulated in four microarray datasets and is also selected in three centrality measures. Further, it interacts with the RA drug targets, JAK1 and JAK2. However, in a preclinical study blocking CCR5 with its antagonists and subsequently testing the effects of CCR5 blocking in a clinical trial with RA patients has not reported any clinical benefit [92] [93] . The C-X-C chemokine receptor type 4 (CXCR4) is up-regulated in four microarray datasets and is selected in two centrality measures. Schmutz et al. have also observed the up-regulation of CXCR4 in synovial tissues [94] . Further, the antagonists of CXCR4 have reduced angiogenesis in the CIA murine models of RA [95] . Some antagonists of CXCR4 such as AMD3100 and a T140 analog have also reduced joint inflammation and the severity of RA [96] [97] . Furthermore, low-level laser irradiation has reduced the expression of CXCR4 in CIA rat models of RA [98] . Even the single nucleotide polymorphisms (SNPs) of some genes such as PTPRC and TNFRSF14 are associated with RA [99] [100] .
In the current study, microarray and human PPI data were combined to generate a cytokine signaling network. We identified key molecules, which are the central proteins of this network with differential expression in RA. We also identified how these key molecules are connected to some of the current RA drug targets. Our strategy is based on a two dimensional information involving PPI and gene expression data. This network-based strategy, which led to the identification of key molecules of the cytokine signaling network, may be used for identifying multiple biomarkers, which may have potential for monitoring therapy responses.
Even though eight of the key molecules were down-regulated, their knowledge can be used for making strategies for drug discovery. For instance, designing drugs in such a way that they (i) enhance the expression of the down-regulated genes or (ii) inhibit the action or expression of a particular molecule which is known to cause the down-regulation of the key molecule (for instance, inhibition of a transcriptional repressor) can be a useful strategy in dealing with the down-regulated genes. In addition, the gene expression signatures which include both the up- and down-regulated genes can be used for screening a library of bioactive small molecules using the connectivity map (CMAP) database [101] . The molecules can further be explored for their exact targets and mechanism. This way, the gene expression signatures can essentially be used in discovering new knowledge from existing knowledge. Moreover, biological systems are robust because the perturbations caused by drug treatments can be restored. Overcoming robustness is likely to be the key factor for finding better drug targets. In this respect, both the up-and down-regulated genes may be leveraged for a multi-targeted approach.
In building the CPPIN network, we did not look for the differential expression of the cytokines in the microarray data. Cytokines are autocrine, paracrine and endocrine signaling molecules and they might be secreted by a bunch of different populated cell types in the synovium and synovial fluid of the patients with RA. Since they come from a variety of sources, they may not be differentially expressed in the microarray data. If they are secreted by other cell types and are present in the microenvironment of RASF, they can induce signaling pathways. All of the reported 12 cytokines in this study are known to be elevated in RA and they are known to activate their corresponding eight transcription factors. Elevated levels of the transcription factors may contribute to the enhanced expression of their target genes. However, an activated transcription factor may induce the expression of its target genes even though it is not differentially expressed but present in enough concentration. Therefore, we did not look for the differentially expressed cytokine and transcription factor pairs for building CPPIN.
In summary, we have built a cytokine signaling network in RA. A combination of network centrality measures and gene expression profiling data has identified 24 key molecules of this network. Two of these are already drug targets for RA while 12 others physically interact with some of the recognized drug targets. Some of these molecules such as EGFR, PTPN6, LCK, CSF2RB, IL2RG, MYC, FOS, CXCR4, PTPRC and TNFRSF14 are well studied in RA by other workers and are reported to play a role in the pathogenesis of RA. However, our strategy Table 5 . An ensemble of current RA drug targets. These are the current RA drug targets that are obtained from two sources namely TTD and a scientific article, Okada et al. [81] . Key molecules of cytokine network in RA The differential expression of the genes which encode these proteins was computed in five synovial microarray datasets. Finally, the genes which are selected in at least three centrality measures and three microarray datasets or two centrality measures and four microarray datasets were considered the key molecules. This resulted in 24 key molecules. Two of these, SYK and JUN, are already current RA drug targets. Among the remaining, 12 have direct PPI links to some of the current RA drug targets.
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herein was to develop a proof-of-principle method for identifying key molecules probably involved in the pathogenesis of RA. Though some of these molecules are well studied in RA, yet their crucial involvement in the disease and their amenability for drug discovery needs to be established.
Conclusions
The present study was focused on developing an approach that can maximize the use of the publicly available PPI and gene expression profiling data from GEO for identifying key molecules for RA. In this study, a comprehensive RA synovial-specific cytokine signaling network with 12 cytokines and 8 of their respective transcription factors has been built. Using a novel approach that combines network centrality measures and differential expression in microarray datasets, we identified 24 key molecules of this network probably involved in the pathogenesis of RA. Two of these molecules, JUN and SYK, are already known drug targets for RA. Of the remaining, 12 have direct PPI links to some of the current drug targets of RA. The scientific literature also provides evidences for the prominence of some of these 24 molecules in the pathogenesis of RA. These molecules, seemingly important to the cytokine signaling network, need to be further studied in order to establish their involvement in the pathogenesis of RA and to explore their potential for developing new therapeutics. 
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